Gland Pharma · NSE: GLAND · BSE: 543245
Q2 FY24 results · Jul–Sep 2023
Gland Pharma reported revenue from operations of ₹1,373.42 crore (up 31.5% from Q2 FY23) and net profit of ₹194.08 crore (down 19.5% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,373.42 | 1,044.40 | +31.5% | 1,208.69 | +13.6% |
| Other income | 53.16 | 65.62 | −19.0% | 37.54 | +41.6% |
| Total income | 1,426.58 | 1,110.03 | +28.5% | 1,246.23 | +14.5% |
| Profit before tax | 289.89 | 324.08 | −10.6% | 261.27 | +11.0% |
| Net profit for the period | 194.08 | 241.24 | −19.5% | 194.10 | −0.0% |
| EPS, basic (₹) | 11.78 | 14.65 | −19.6% | 11.79 | −0.1% |
| Net margin (%) | 14.1 | 23.1 | 16.1 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,010.67 | 1,048.31 | −3.6% | 884.07 | +14.3% |
| Other income | 41.11 | 65.62 | −37.3% | 35.21 | +16.8% |
| Total income | 1,051.78 | 1,113.93 | −5.6% | 919.28 | +14.4% |
| Profit before tax | 347.06 | 322.47 | +7.6% | 253.99 | +36.6% |
| Net profit for the period | 257.53 | 239.63 | +7.5% | 187.58 | +37.3% |
| EPS, basic (₹) | 15.64 | 14.55 | +7.5% | 11.39 | +37.3% |
| Net margin (%) | 25.5 | 22.9 | 21.2 |
Consolidated
- Filed with BSE
- 07 Nov 2023, 15:45 IST
- Board meeting
- 06 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2023, 15:45 IST
- Board meeting
- 06 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE